Sodium-glucose cotransporter 2 (SGLT2) inhibitors, a class of antidiabetic medications, have demonstrated significant cardiovascular (CV) benefits, including reducing hospitalization for HF. Here, SLC5A2 is linked to hydrops fetalis.